<DOC>
	<DOCNO>NCT00308087</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment rituximab plus sargramostim effective rituximab alone .</brief_summary>
	<brief_title>Comparison Study Rituximab Plus Sargramostim Rituximab Alone Relapsed Follicular B-cell Lymphoma , Form Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>On 29 May 2009 , Bayer begin transition sponsorship trial Genzyme . As 29 August 2009 , Genzyme assume responsibility close study . NOTE : This study originally post sponsor Berlex , Inc. Berlex , Inc. rename Bayer HealthCare , Inc . The study terminate early due low enrollment ; significant change protocol would require keep pace change therapeutic landscape indolent lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion Criteria ( abbreviated list ) : Relapsed follicular Bcell lymphoma One previous therapy nonHodgkin 's At least one measurable tumor CT scan MRI Additional criterion determine screen visit Exclusion Criteria ( abbreviated list ) : Rituximab refractory ( le 6 month last treatment rituximab relapse ) Currently receive treatment another cancer Infection currently treat Active Hepatitis B History HIV infection Pregnant Additional criterion determine screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Sargramostim</keyword>
	<keyword>Leukine</keyword>
	<keyword>NHL</keyword>
</DOC>